Clinical Trials Logo

Pharmacokinetics clinical trials

View clinical trials related to Pharmacokinetics.

Filter by:

NCT ID: NCT05098080 Active, not recruiting - Pharmacokinetics Clinical Trials

Hutrukin to Analyze Safety and PK in Healthy Volunteers

Start date: April 10, 2023
Phase: Phase 1
Study type: Interventional

The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).

NCT ID: NCT05090280 Completed - Pharmacokinetics Clinical Trials

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat

MPAR-101
Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.

NCT ID: NCT05076864 Recruiting - Acute Kidney Injury Clinical Trials

Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study.

LEFKIP
Start date: January 1, 2020
Phase:
Study type: Observational

Evaluation of the pharmacokinetics of levosimendan and its metabolites in intensive care patients with normal, reduced and dialysis supported renal function.

NCT ID: NCT05065775 Completed - Anesthesia Clinical Trials

Bioavailability of Intranasal Dexmedetomidine

INDEX
Start date: November 1, 2021
Phase: Phase 4
Study type: Interventional

Aim of this study is to characterize the pharmacokinetics of dexmedetomidine in supine, anesthetized adult patients after intranasal dosing.

NCT ID: NCT05042674 Recruiting - Pharmacokinetics Clinical Trials

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

Start date: September 20, 2021
Phase: N/A
Study type: Interventional

A trial on acute antioxidant protection and immune effects when 24 people consume a novel nutraceutical blend compared to a placebo on different test days.

NCT ID: NCT05041699 Recruiting - Pharmacokinetics Clinical Trials

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Start date: June 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A double-blind, randomized trial (1:1) to characterize the local and systemic pharmacokinetics (PK) of two DPV-LNG vaginal ring formulations

NCT ID: NCT05036421 Completed - Pharmacokinetics Clinical Trials

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Start date: February 15, 2022
Phase: Phase 3
Study type: Interventional

The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects

NCT ID: NCT05005520 Completed - Healthy Volunteers Clinical Trials

Study of DTRI-031 in Healthy Volunteers

Start date: October 20, 2021
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, single center, placebo-controlled phase 1 study in healthy volunteers to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single intravenous (iv) injection of DTRI-031

NCT ID: NCT04971837 Completed - Pharmacokinetics Clinical Trials

Interaction Between Cannabidiol, Meal Ingestion, and Liver Function

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

According to a recent consumer poll, over 20 million Americans regularly use cannabidiol (CBD). Moreover, 64 million Americans (over 25% of the population) report trying CBD at least once within the previous 2 years. Since the passing of the 2018 Agriculture Improvement Act, the use of hemp-derived products, such as CBD, is highly prevalent across North America. The acceleration of the use of CBD has outpaced our understanding of the associated potential risks and benefits, and the way it is processed within the body. In the current proposed project, investigators wish to continue our ongoing collaboration with Caliper Foods, a Colorado-based manufacturer of CBD products. The focus of this project is three-fold: (1) investigators will compare the pharmacokinetics of different formulations of ingestible CBD; (2) investigators will examine the potential two-way interaction between a meal and one formulation of ingestible CBD; and, (3) investigators will examine the influence of different formulations of CBD on markers of liver function.

NCT ID: NCT04969965 Completed - Healthy Volunteers Clinical Trials

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

Start date: June 21, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label and uncontrolled study to evaluate the comparative PK of EQ143 following oral single dose administration in adult healthy volunteers different racial and ethnic populations. A total of one (1) single dose cohort is planned at 110 mg of EQ143. EQ143 is an approved therapy in China at the 110 mg dose for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) T790Mmutation-positive, metastatic non-small cell lung cancer (NSCLC), who have progressed during or after EGFR tyrosine kinase inhibitor (TKI) therapy. A total of 45 (15 Caucasian, 8 Black/African American and 7 Hispanic/Latino, and 15 ethnic Chinese)